Since joining Kirkland & Ellis, Jing's representative experience includes:
- Represented the joint sponsors and underwriters on the global offering and listing of Dida Inc. (HKSE: 02559) on The Stock Exchange of Hong Kong Limited on June 28, 2024. China International Capital Corporation Hong Kong Securities Limited, Haitong International Capital Limited and Nomura International (Hong Kong) Limited acted as the joint sponsors for this transaction
- Represented the underwriters in the initial public offering and listing of BingEx Limited, a leading independent on-demand courier service provider in China, on the Nasdaq Stock Market under the symbol “FLX”
- Representing the underwriters in the initial public offering of a Chinese leading IoT software service company in the U.S.
- Represented a Chinese leading biotechnology company (focused on oncology therapeutics) in its listing on Nasdaq
- Represented Tims China (NASDAQ: THCH), Canadian Solar (NASDAQ: CSIQ), Fanhua Inc. (NASDAQ: FANH) and MoneyHero Limited (NASDAQ: MNY) in their post-U.S. listing compliance matters
- Represented Goldman Sachs (Asia) L.L.C., Citigroup Global Markets Limited and J.P. Morgan Securities (Asia Pacific) Limited, in connection with the H-share placing of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. The net proceeds from the H-Share Placing amounted to approximately HK$541.4 million
- Represented Will Semiconductor Co., Ltd. Shanghai (SHA: 603501), a global leading fabless semiconductor company, in its US$445 million offering of 31,000,000 global depositary receipts. This transaction marked the largest offshore listing by a China-based semiconductor company since 2005. This transaction was named “Deals of the Year 2023” by China Business Law Journal
- Represented ZX Inc. (HKSE: 9890), a leading online game products publisher in China, on its global offering and listing on the Hong Kong Exchanges and Clearing Limited on September 28, 2023
- Represented the joint sponsors and underwriters on the global offering and listing of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKSE: 1541), a leading science-driven biotechnology company dedicated to the development of immuno-oncology therapies in China, on the Hong Kong Exchanges and Clearing Limited on September 5, 2023
- Represented Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKSE: 6990) on its US$174 million global offering and listing on the Stock Exchange of Hong Kong Limited on July 11, 2023. This transaction was named “Best IPO - Hong Kong SAR” by FinanceAsia Achievement Awards 2023
Prior to joining Kirkland & Ellis, Jing's representative experience includes:
- Represented Morgan Stanley, CICC and Credit Suisse as the joint sponsors in the US$281 million global offering and listing of SciClone Pharmaceuticals (HKSE: 6600), a China-focused biopharmaceutical company specializing in oncology and severe infection, on the Main Board of the Hong Kong Stock Exchange
- Represented Morgan Stanley and CICC as the joint sponsors in the US$394.5 million global offering and listing of Cheerwin Group Limited (HKSE: 6601), a leading multi-category household care and personal care platform in China, on the Main Board of The Hong Kong Stock Exchange
- Represented China Bohai Bank (HKSE: 9668), a national joint-stock commercial bank in China, in its US$1.77 billion global offering and listing of its H shares on the Main Board of the Hong Kong Stock Exchange
- Represented Credit Suisse, Morgan Stanley, and ICBC International Capital as the joint sponsors in the US$381 million global offering and listing of JS Global Lifestyle (HKSE: 1691), a global leader in innovative small household appliances, on the Main Board of The Hong Kong Stock Exchange
- Represented Jinshang Bank (HKSE: 2558), the only provincial city commercial bank in Shanxi Province, in its US$422 million global offering and listing of its H shares on the Main Board of the Hong Kong Stock Exchange
